Status:
UNKNOWN
Mitoquines in COPD
Lead Sponsor:
Hospital Universitario Marqués de Valdecilla
Collaborating Sponsors:
GlaxoSmithKline
Conditions:
COPD Exacerbation
Eligibility:
All Genders
40-100 years
Brief Summary
The most important pathogenic factor of Chronic Obstructive Pulmonary Disease (COPD) in the Western world is chronic exposure to tobacco smoke, which induces oxidative stress not only in the respirato...
Detailed Description
INTRODUCTION Chronic Obstructive Pulmonary Disease (COPD) is characterized by progressive and hardly reversible obstruction of the airways, which basically affects the small airways (chronic obstructi...
Eligibility Criteria
Inclusion
- Stable COPD (40 years or older with baseline post-bronchodilator forced expiratory volume in 1 s \[FEV1\]/forced vital capacity \[FVC\] ≤0.70) will be recruited during their regular follow-up.
- Control group: age- and sex-matched volunteers without previous diagnosis of COPD or 6 other respiratory conditions, and with post-bronchodilator forced expiratory volume in 1 s (FEV1)/forced vital capacity \[FVC\]=0.70.
- Exacerbated patients (patients 48h after being admited in Hospital due to severe COPD exacerbation.
Exclusion
- Patients with renal failure or other severe chronic or acute conditions.
- Patients with exacerbations in the previous 6 weeks.
Key Trial Info
Start Date :
July 1 2020
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
June 1 2021
Estimated Enrollment :
180 Patients enrolled
Trial Details
Trial ID
NCT04449419
Start Date
July 1 2020
End Date
June 1 2021
Last Update
June 26 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Hospital Universitario Marqués de Valdecilla
Santander, Cantabria, Spain, 39005